Adagene presents trial data showing muzastotug combination benefits Apr 17, 2026 04:01PM
H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG) Apr 7, 2026 07:49AM
Adagene Inc (ADAG) PT Raised to $10 at Guggenheim Apr 6, 2026 06:41AM
Adagene Inc (ADAG) PT Raised to $8 at Leerink Partners Apr 2, 2026 02:53PM
Adagene partners with Incyte for cancer drug combination study Apr 2, 2026 07:01AM


Nov 24, 2025 06:12AM Guggenheim Starts Adagene Inc (ADAG) at Buy
Nov 13, 2025 07:03AM Adagene licenses SAFEbody technology to Third Arc Bio for $5M upfront
Sep 18, 2025 07:06AM Lucid Capital Markets Starts Adagene Inc (ADAG) at Buy, PT $9
Sep 3, 2025 09:05AM Adagene names Axel Hoos as executive advisor
Aug 15, 2025 06:53AM Adagene Inc (ADAG) PT Lowered to $7 at H.C. Wainwright
Aug 6, 2025 06:20AM Leerink Partners Starts Adagene Inc (ADAG) at Outperform
Jul 15, 2025 07:01AM Adagene receives FDA guidance for phase 2 colorectal cancer trial
Jul 8, 2025 07:01AM Adagene (ADAG) partners with ConjugateBio for antibody drug conjugate development
Jul 1, 2025 07:02AM Adagene (ADAG) announces up to $25 million strategic investment from Sanofi (SNY)
May 22, 2025 05:08PM Adagene Inc. (ADAG) updates data from Phase 1b/2 study of Muzastotug
Jan 27, 2025 07:12AM Adagene Inc (ADAG) PT Raised to $8 at H.C. Wainwright
Jan 27, 2025 07:01AM Adagene Inc. (ADAG) Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 21, 2025 05:00PM Adagene Inc. (ADAG) to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Nov 15, 2024 01:50PM Jefferies Downgrades Adagene Inc (ADAG) to Hold
Sep 19, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG)